Jonas Bergquist, MD, PhD, is a Full Chair Professor in Analytical Chemistry and Neurochemistry at the Department of Chemistry at Uppsala University. He also has served as an Associate Professor of Clinical Neuroscience at the Sahlgrenska University Hospital and Gothenburg University, Gothenburg, Sweden. In 1999, he became a Researcher in Uppsala University, Uppsala, Sweden. In 2005, he was appointed the Chaired Professor of Analytical Chemistry and Neurochemistry, heading the Bergquist group at the Department of Chemistry, Biomedical Centre, Uppsala University. Since 2011, he is an Adjunct Professor of Pathology at the University of Utah, Salt Lake City, US, and since 2015, a Professor of Precision Medicine, Binzhou Medical University, Yantai, China.
Research interests: various neurodegenerative diseases such as Parkinson's, Alzheimer's, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS); his research "involves methods to measure substances that can act as biomarkers for early diagnosis and contribute to the understanding of what initiates the disease process... [and] measure not only the individual substances but also seek patterns and monitor how they change during illness,... [the Bergquist group's] specialty is the analysis of cerebrospinal fluid and its chemical composition."
Working groups and committees[edit | edit source]
ME/CFS Collaborative Research Center at Stanford University[edit | edit source]
Member of the Working Group which offers their expertise and resources to the ME/CFS Collaborative Research Center at Stanford University.
EUROMENE[edit | edit source]
Dr. Bergquist is a member of the Biomarkers Working Group of ME/CFS across Europe on behalf of the EUROMENE, a European Union COST Action CA15111 not-for-profit research organization committed to tackling the cause and treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
ME/CFS Common Data Element (CDE) Project[edit | edit source]
Member of the Biomarkers Working Group and Neurologic/Cognitive/CNS Imaging Working Group of the Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Common Data Element (CDE) Project sponsored by the National Institute of Neurological Disorders and Stroke and the Centers for Disease Control and Prevention.
2017 Ramsay Award[edit | edit source]
A team comprised of Dr. Bergquist and Dr. Jonas Blomberg of Uppsala University and Dr. Carl-Gerhard Gottfries and Dr. Olof Zachrisson of the Gottfries Clinic were awarded a 2017 Ramsay Award grant from the Solve ME/CFS Initiative for research into biomarkers for initiation (infection) and metabolic derangement in ME/CFS.
Talks and interviews[edit | edit source]
- 2015, Speaker at the 10th Invest in ME International ME Conference - (no speech title given) DVD available
- 12 Aug 2017, Community Symposium on the Molecular Basis of ME/CFS - 2017: Speech title - In search of biomarkers revealing pathophysiology in a Swedish ME/CFS patient cohort
- 3-5 May 2018, ME/CFS Canadian Collaborative Team Conference - Speech title: The Biochemistry to Support the Evidence of Neuroinflammatory Involvement in ME/CFS
- 29 Sep 2018, The Neuroimmune Route in ME/CFS, given at Second Annual Community Symposium on the Molecular Basis of ME/CFS, sponsored by Open Medicine Foundation - (Video)
- 14 Mar 2019, Targeted Molecular Diagnosis of ME/CFS – the Devil is in the Details, given at the International Research Symposium, Geelong, Australia, sponsored by Emerge Australia
Research studies on ME/CFS[edit | edit source]
- 2011, Distinct Cerebrospinal Fluid Proteomes Differentiate Post-Treatment Lyme Disease from Chronic Fatigue Syndrome - (Full Text)
References[edit | edit source]
- "ME/CFS Canadian Collaborative Team Conference program" (PDF). Retrieved Mar 6, 2019.
- Johansson, Åke. "Jonas Bergquist - Uppsala University, Sweden". katalog.uu.se. Retrieved Apr 25, 2019.
- "OMF grants $1.2M to Ramp Up Collaborative Research Center at Stanford University". bos.etapestry.com. Retrieved Apr 25, 2019.
- "Action CA15111". COST. Retrieved Apr 25, 2019.
- "Complete Myalgic Encephalomyelitis/Chronic Fatigue Syndrome CDE Roster". NIH. Retrieved Oct 11, 2019.
- "2017 Ramsay Award Program Results". Solve ME/CFS Initiative. Retrieved Apr 25, 2019.
- Schutzer, Steven E; Angel, Thomas E.; Liu, Tao; Schepmoes, Athena A.; Clauss, Therese R.; Adkins, Joshua N.; Camp, David G.; Holland, Bart K.; Bergquist, Jonas; Coyle, Patricia K.; Smith, Richard D.; Fallon, Brian A.; Natelson, Benjamin (2011), "Distinct Cerebrospinal Fluid Proteomes Differentiate Post-Treatment Lyme Disease from Chronic Fatigue Syndrome", PLoS ONE, 6 (2), doi:10.1371/journal.pone.0017287
cognition - Thought processes, including attention, reasoning, and memory.
central nervous system (CNS) - One of the two parts of the human nervous system, the other part being the peripheral nervous system. The central nervous system consists of the brain and spinal cord, while the peripheral nervous system consists of nerves that travel from the central nervous system into the various organs and tissues of the body.
myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.
chronic fatigue syndrome (CFS) - A controversial term, invented by the U.S. Centers for Disease Control, that generally refers to a collection of symptoms as “fatigue”. There have been multiple attempts to come up with a set of diagnostic criteria to define this term, but few of those diagnostic criteria are currently in use. Previous attempts to define this term include the Fukuda criteria and the Oxford criteria. Some view the term as a useful diagnostic category for people with long-term fatigue of unexplained origin. Others view the term as a derogatory term borne out of animus towards patients. Some view the term as a synonym of myalgic encephalomyelitis, while others view myalgic encephalomyelitis as a distinct disease.